Literature DB >> 10472424

Caudate size in first-episode neuroleptic-naive schizophrenic patients measured using an artificial neural network.

P W Corson1, P Nopoulos, N C Andreasen, D Heckel, S Arndt.   

Abstract

BACKGROUND: Structural brain imaging studies have demonstrated an increase in caudate volume in schizophrenic patients medicated with typical neuroleptics and a volume decrease following treatment with atypical neuroleptics. The measurement of striatal volume in patients who have never been treated with neuroleptics may indicate whether these changes are superimposed on intrinsic basal ganglia pathology in schizophrenia or are solely neuroleptic-induced.
METHODS: We studied 36 first-episode, neuroleptic-naive schizophrenic patients and 43 control subjects using an artificial neural network (ANN) to identify and measure the caudate nucleus. The resulting volumes were analyzed using an ANCOVA controlling for intracranial volume, age, gender, and socioeconomic status.
RESULTS: The mean volume difference between the caudate nuclei of patients and control subjects was .297 mL, the caudate nuclei of the patients being smaller than those of controls. When we covaried for intracranial volume, this was a statistically significant difference in caudate volume (n = 79; df = 1,75; F = 4.18; p > .04).
CONCLUSIONS: Caudate nuclei of neuroleptic naive schizophrenic patients are significantly smaller than those of controls. This suggests that patients suffering from schizophrenia may have intrinsic pathology of the caudate nucleus, in addition to the pathology observed as a consequence of chronic neuroleptic treatment.

Entities:  

Mesh:

Year:  1999        PMID: 10472424     DOI: 10.1016/s0006-3223(99)00079-7

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  32 in total

1.  MRI study of caudate nucleus volume and its cognitive correlates in neuroleptic-naive patients with schizotypal personality disorder.

Authors:  James J Levitt; Robert W McCarley; Chandlee C Dickey; Martina M Voglmaier; Margaret A Niznikiewicz; Larry J Seidman; Yoshio Hirayasu; Aleksandra A Ciszewski; Ron Kikinis; Ferenc A Jolesz; Martha E Shenton
Journal:  Am J Psychiatry       Date:  2002-07       Impact factor: 18.112

Review 2.  [Changes in brain structure caused by neuroleptic medication].

Authors:  H Scherk; P Falkai
Journal:  Nervenarzt       Date:  2004-11       Impact factor: 1.214

3.  Different gray matter patterns in chronic schizophrenia and chronic bipolar disorder patients identified using voxel-based morphometry.

Authors:  Vicente Molina; Gemma Galindo; Benjamín Cortés; Alba G Seco de Herrera; Ana Ledo; Javier Sanz; Carlos Montes; Juan A Hernández-Tamames
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2010-12-28       Impact factor: 5.270

Review 4.  Predictors and markers of clozapine response.

Authors:  Carmen Chung; Gary Remington
Journal:  Psychopharmacology (Berl)       Date:  2005-02-17       Impact factor: 4.530

5.  An elliptic PDE approach for shape characterization.

Authors:  Haissam Haidar; Sylvain Bouix; James Levitt; Robert W McCarley; Martha E Shenton; Janet S Soul
Journal:  Conf Proc IEEE Eng Med Biol Soc       Date:  2004

6.  Characterizing the shape of anatomical structures with Poisson's equation.

Authors:  Haissam Haidar; Sylvain Bouix; James J Levitt; Robert W McCarley; Martha E Shenton; Janet S Soul
Journal:  IEEE Trans Med Imaging       Date:  2006-10       Impact factor: 10.048

7.  Structural analysis of the basal ganglia in schizophrenia.

Authors:  Daniel Mamah; Lei Wang; Deanna Barch; Gabriel A de Erausquin; Mokhtar Gado; John G Csernansky
Journal:  Schizophr Res       Date:  2006-10-30       Impact factor: 4.939

8.  Sleep dysfunction and thalamic abnormalities in adolescents at ultra high-risk for psychosis.

Authors:  Jessica R Lunsford-Avery; Joseph M Orr; Tina Gupta; Andrea Pelletier-Baldelli; Derek J Dean; Ashley K Smith Watts; Jessica Bernard; Zachary B Millman; Vijay A Mittal
Journal:  Schizophr Res       Date:  2013-10-04       Impact factor: 4.939

9.  Reduced binding potential of GABA-A/benzodiazepine receptors in individuals at ultra-high risk for psychosis: an [18F]-fluoroflumazenil positron emission tomography study.

Authors:  Jee In Kang; Hae-Jeong Park; Se Joo Kim; Kyung Ran Kim; Su Young Lee; Eun Lee; Suk Kyoon An; Jun Soo Kwon; Jong Doo Lee
Journal:  Schizophr Bull       Date:  2013-04-15       Impact factor: 9.306

10.  Regional patterns and clinical correlates of basal ganglia morphology in non-medicated schizophrenia.

Authors:  Martina Ballmaier; Florian Schlagenhauf; Arthur W Toga; Jürgen Gallinat; Michael Koslowski; Michele Zoli; Cornelius Hojatkashani; Katherine L Narr; Andreas Heinz
Journal:  Schizophr Res       Date:  2008-09-24       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.